Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
Want to see MNPR full AI Analyst Report?
Top Page
Monopar Therapeutics Inc
(NASDAQ:MNPR)
Select Model
Select Model
Rating:53Neutral
Price Target:
$65.00
▲(15.62% Upside)
Action:Reiterated
Date:05/30/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn despite low leverage). Offsetting factors include constructive technical momentum and a strong set of positive, late-stage clinical/corporate updates; valuation remains constrained by losses and no dividend support.
Positive Factors
Late-stage clinical efficacy
Robust Phase 3 FoCus results showing superior neurologic improvement versus standard care, sustained benefits for ~3 years across long follow-up, and favorable safety strengthen the program's clinical and regulatory credibility, materially increasing the probability of eventual approval and long-term market impact.
Negative Factors
No revenue; rising losses
The company remains pre‑revenue with materially worsening net losses, meaning operational viability depends on future regulatory success and external funding. Persistent losses weaken return metrics and create structural execution risk until product revenues materialize or sustainable partnerships emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage clinical efficacy
Robust Phase 3 FoCus results showing superior neurologic improvement versus standard care, sustained benefits for ~3 years across long follow-up, and favorable safety strengthen the program's clinical and regulatory credibility, materially increasing the probability of eventual approval and long-term market impact.
Read all positive factors
Monopar Therapeutics Inc (MNPR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$451.99M
Dividend YieldN/A
Average Volume (3M)166.73K
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue GrowthN/A
EPS Growth40.38%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.07
Shares Outstanding6,699,062
10 Day Avg. Volume123,716
30 Day Avg. Volume166,732
Financial Highlights & Ratios
PEG Ratio-0.98
Price to Book (P/B)3.51
Price to Sales (P/S)0.00
P/FCF Ratio-39.66
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-24.23
Forecast
1Y Price Target
$111.89Price Target Upside99.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.66
Revenue Forecast (FY)N/A
Monopar Therapeutics Inc Business Overview & Revenue Model
Company Description
Monopar Therapeutics Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to pioneering novel cancer treatments within the United States. Its leading investigational drug, Validive, a specialized clonidine hydrochloride mu...
How the Company Makes Money
As a clinical-stage biotechnology company, Monopar Therapeutics does not have a disclosed, established product-sales business and typically does not generate recurring revenue from marketed drugs; instead, its operations are generally funded throu...
Monopar Therapeutics Inc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.64M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net Income | -14.98M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
Balance Sheet | ||||||
| Total Assets | 137.98M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Cash, Cash Equivalents and Short-Term Investments | 137.49M | 140.40M | 60.21M | 7.27M | 13.12M | 20.30M |
| Total Debt | 131.56K | 154.92K | 0.00 | 0.00 | 8.41K | 0.00 |
| Total Liabilities | 2.59M | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M |
| Stockholders Equity | 135.39M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
Cash Flow | ||||||
| Free Cash Flow | -10.01M | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Operating Cash Flow | -10.01M | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Investing Cash Flow | -68.71M | -63.45M | -14.34M | 4.93M | -4.92M | 0.00 |
| Financing Cash Flow | 91.49M | 91.57M | 59.29M | 2.03M | 32.87K | 10.88M |
Monopar Therapeutics Inc Technical Analysis
Positive
56.22
Price Trends
59.21
Positive
58.41
Positive
66.60
Positive
Market Momentum
1.05
Negative
66.27
Neutral
78.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Positive. The current price of 56.22 is below the 20-day moving average (MA) of 62.15, below the 50-day MA of 59.21, and below the 200-day MA of 66.60, indicating a bullish trend. The MACD of 1.05 indicates Negative momentum. The RSI at 66.27 is Neutral, neither overbought nor oversold. The STOCH value of 78.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MNPR.
Monopar Therapeutics Inc Risk Analysis
Monopar Therapeutics Inc disclosed 77 risk factors in its most recent earnings report. Monopar Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monopar Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $451.99M | -38.43 | -12.84% | ― | ― | 40.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $327.34M | -3.84 | -121.71% | ― | ― | ― | |
47 Neutral | $348.79M | ― | -61.41% | ― | 8.16% | -434.76% | |
47 Neutral | $362.04M | -2.09 | -486.41% | ― | 395.85% | 21.44% | |
46 Neutral | $82.73M | -1.85 | -95.50% | ― | -10.71% | 28.59% | |
46 Neutral | $49.39M | -1.39 | -81.25% | ― | ― | 28.17% |
* Healthcare Sector Average
MNPR
Monopar Therapeutics Inc
67.47
34.61
105.33%
CRDF
Cardiff Oncology
1.21
-1.89
-60.97%
VNDA
Vanda
5.80
1.29
28.60%
VSTM
Verastem
4.12
-0.81
-16.43%
MREO
Mereo Biopharma Group Plc
0.31
-2.54
-89.16%
SLN
Silence Therapeutics
6.93
0.98
16.47%
Monopar Therapeutics Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
Positive
May 29, 2026
On May 29, 2026, Monopar Therapeutics presented results from a Phase 2 study of ALXN1840 (tiomolibdate choline) in patients with Wilson disease at the European Association for the Study of the Liver International Liver Congress 2026. The trial eva...
Business Operations and StrategyProduct-Related Announcements
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
Positive
May 19, 2026
On May 19, 2026, Monopar Therapeutics reported that Hepatology Communications published Phase 2 data showing its investigational drug ALXN1840 (tiomolibdate choline) significantly improved copper balance in nine patients with Wilson disease. The o...
Business Operations and StrategyProduct-Related Announcements
Monopar Highlights Strong Phase 3 Data for ALXN1840
Positive
Apr 20, 2026
On April 19, 2026, Monopar Therapeutics reported new analyses from the randomized Phase 3 FoCus trial showing that ALXN1840 (tiomolibdate choline) delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologi...
Business Operations and StrategyExecutive/Board Changes
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez
Positive
Mar 2, 2026
On March 2, 2026, Monopar Therapeutics Inc. announced it had appointed veteran biopharma executive Susan Rodriguez as its Chief Commercial and Strategy Officer, a newly created role. Rodriguez, who has over 30 years of industry experience, will sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.